



## Drug-Induced Hepatotoxicity: From Pathology to Novel Therapeutic Approaches

Guest Editor:

**Dr. Sanda Win**

Division of Gastrointestinal and  
Liver Disease, Department of  
Medicine, Keck School of  
Medicine, University of Southern  
California, 2011 Zonal Ave., HMR  
612, Los Angeles, CA 90089, USA

Deadline for manuscript  
submissions:

**closed (31 July 2022)**

### Message from the Guest Editor

The liver is the main organ for metabolized and detoxification chemicals and is susceptible to the toxicity of these agents. Drugs associated with Drug-induced liver injury (DILI) may cause injury in a dose-dependent, predictable hepatotoxicity or in an unpredictable hepatotoxicity in susceptible individuals. Drugs or their toxic metabolites cause the activation of MAP kinases or deactivation of signaling pathways. Then, it causes the impairment of mitochondrial function, oxidative stress, mitochondria damaged, and hepatocyte death.

Moreover, the endogenous defense system of the liver is made up of endogenous nonprotein antioxidants and endogenous protein antioxidants. The main endogenous antioxidants are glutathione, lipoic acid, bilirubin, ferritin, superoxide dismutase, catalase, and glutathione peroxidase. Their main function is to maintain redox homeostasis in the liver.

The aim of this Special Issue on Drug-Induced Hepatotoxicity is to discuss updated recent findings in mechanisms of drug induced hepatotoxicity and potential therapeutic targets. Original articles and review articles on the following topics are welcome.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)